Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer
2024 · Cancer Letters · 18 citations
https://doi.org/10.1016/j.canlet.2024.217124
R
Ryota Nakamura
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
78
Papers
331
Citations
11
h-index
12
i10-index
Ryota Nakamura is an academic researcher from Juntendo University Urayasu Hospital. The author has contributed to research in topics: Phagocytosis and Immune Regulation & Pancreatic and Hepatic Oncology Research & Pancreatitis Pathology and Treatment. The author has an h-index of 11, co-authored 67 publications.
ORCID: 0000-0001-9519-2276Papers by this author
worksYAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
2024 · Clinical Cancer Research · 5 citations
https://doi.org/10.1158/1078-0432.ccr-24-1762
Figure S5 from Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
2024 · 0 citations
https://doi.org/10.1158/1535-7163.25124977
Data from Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
2024 · 0 citations
https://doi.org/10.1158/1535-7163.c.7054186.v1
Figure S7 from Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
2024 · 0 citations
https://doi.org/10.1158/1535-7163.25124971
Figure S3 from Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
2024 · 0 citations
https://doi.org/10.1158/1535-7163.25124983.v1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat